Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma: Should these be treated as different diseases?

Deborah A. Thomas; Susan O'Brien; Stefan Faderl; John T. Manning; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Jeffrey Medeiros; Jorge Cortes; Hagop Kantarjian

doi:10.1007/s11899-010-0076-4

Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma: Should these be treated as different diseases?

Deborah A. Thomas, Susan O'Brien, Stefan Faderl, John T. Manning, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Jeffrey Medeiros, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, "B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL." This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.

Original language	English (US)
Pages (from-to)	58-66
Number of pages	9
Journal	Current Hematologic Malignancy Reports
Volume	6
Issue number	1
DOIs	https://doi.org/10.1007/s11899-010-0076-4
State	Published - Mar 2011
Externally published	Yes

Keywords

Atypical Burkitt
Burkitt
Burkitt-like
DLBCL
Non-Hodgkin lymphoma
Therapy
WHO classification
c-myc

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11899-010-0076-4

Cite this

@article{72ec9844e1354aebb346266790aedcbf,

title = "Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma: Should these be treated as different diseases?",

abstract = "Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, {"}B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL.{"} This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.",

keywords = "Atypical Burkitt, Burkitt, Burkitt-like, DLBCL, Non-Hodgkin lymphoma, Therapy, WHO classification, c-myc",

author = "Thomas, {Deborah A.} and Susan O'Brien and Stefan Faderl and Manning, {John T.} and Jorge Romaguera and Luis Fayad and Fredrick Hagemeister and Jeffrey Medeiros and Jorge Cortes and Hagop Kantarjian",

year = "2011",

month = mar,

doi = "10.1007/s11899-010-0076-4",

language = "English (US)",

volume = "6",

pages = "58--66",

journal = "Current Hematologic Malignancy Reports",

issn = "1558-8211",

publisher = "Springer Science + Business Media",

number = "1",

}

TY - JOUR

T1 - Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma

T2 - Should these be treated as different diseases?

AU - Thomas, Deborah A.

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Manning, John T.

AU - Romaguera, Jorge

AU - Fayad, Luis

AU - Hagemeister, Fredrick

AU - Medeiros, Jeffrey

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2011/3

Y1 - 2011/3

N2 - Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, "B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL." This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.

AB - Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, "B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL." This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.

KW - Atypical Burkitt

KW - Burkitt

KW - Burkitt-like

KW - DLBCL

KW - Non-Hodgkin lymphoma

KW - Therapy

KW - WHO classification

KW - c-myc

UR - http://www.scopus.com/inward/record.url?scp=79551473158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551473158&partnerID=8YFLogxK

U2 - 10.1007/s11899-010-0076-4

DO - 10.1007/s11899-010-0076-4

M3 - Article

C2 - 21191675

AN - SCOPUS:79551473158

SN - 1558-8211

VL - 6

SP - 58

EP - 66

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

IS - 1

ER -

Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma: Should these be treated as different diseases?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this